Anthem, Novo Nordisk team up for real-world diabetes drug study

Anthem’s outcomes research unit, HealthCore, and Novo Nordisk (NYSE:NVO) have joined forces to study Novo Nordisk’s semaglutide GLP-1 receptor agonist in people with Type 2 diabetes.
The real-world trial is designed to compare the long-term effectiveness of the drug, also known as Ozempic, against 40 other medications among 2,250 adults with Type 2 diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Anthem, Novo Nordisk team up for real-world diabetes drug study appeared first on MassDevice.

Source: Mass Device - October 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Pharmaceuticals Wall Street Beat Anthem Inc. Novo Nordisk Source Type: news